Rochtain agus Imeascadh
Aonad 4A, Áras Dargan, An Ceantar Theas, An Bóthar Míleata, Cill Mhaighneann, Baile Átha Cliath 8, D08 NN9V

Access & Integration
Unit 4a, the Dargan Building, Heuston South Quarter, Military Road, Kilmainham, Dublin 8, D08 NN9V

www.hse.ie
@hselive
t 01 795 9972
e accessandIntegration@hse.ie

MEMORANDUM

To	Pharmacy Executive Manager, Children's Health Ireland
From	Access and Integration Drug Management Programme
Subject	New HSE-Approved Medicinal Product(s) – Dolutegravir sodium, abacavir, lamivuduine (Triumeq®)
Date	18/02/2025

Dear Colleagues,

The following medicinal product has received HSE approval for pricing and reimbursement.

Medicinal Product(s)	**Price to Wholesaler (excluding VAT)**
Dolutegravir sodium, abacavir, lamivuduine (Triumeq®) 5 mg/60 mg/30 mg dispersible tablets x 90	€283.38

Active Ingredient(s)	Dolutegravir sodium, abacavir, lamivuduine
Date of Approval	06/02/2025
Manufacturer	ViiV Healthcare BV
ATC Code and Pharmacotherapeutic Group	J05AR13; Antivirals for systemic use, antivirals for treatment of HIV infections, combinations.
HSE-Approval Details	For the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infected children of at least 3 months of age and weighing at least 6kg to less than 25kg.
Licensed Indication(s)	As listed in the Summary of Product Characteristics (SmPC).
Details of HSE Price Agreements (if applicable)	Centrally agreed Commercial in Confidence Patient Access Scheme in place that ViiV Healthcare will share with hospitals directly. The product will be reimbursed in the same manner that drugs of this category are currently being reimbursed. Under the current IPHA Agreement, hospitals can negotiate revised arrangements with individual manufacturers.
Additional Information	

Best wishes,

Access and Integration Drug Management Programme